Yesterday it was reported that the Non-Executive of Canopy Growth (CGC), David Angelo Lazzarato, exercised options to sell 1,010 CGC shares for a total transaction value of $23.13K.
See today’s analyst top recommended stocks >>
Based on Canopy Growth’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $108 million and quarterly net profit of $457 million. In comparison, last year the company earned revenue of $90.48 million and had a GAAP net loss of $186 million. The company has a one-year high of $28.89 and a one-year low of $9.00.
CGC is a controversial stock, with 3 analysts recommending Buy, while 3 recommends selling the stock. Based on 16 analyst ratings, the analyst consensus is Hold with an average price target of $18.58, reflecting a -8.8% downside. One of the top 25 analysts, according to TipRanks.com, recently recommended Hold CGC with a $21.00 price target.
The insider sentiment on Canopy Growth has been negative according to 29 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Canopy Growth Corp. engages in the production and sale of medical cannabis. The company offers products including oils and concentrates, soft gel capsules and hemp. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.
Read More on CGC:
